Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
Valo Health’s $2.8 Billion Merger with Khosla Ventures Acquisition Co.
Social Finance’s Business Combination with Social Capital Hedosophia Holdings Corp. V
Goodwin Procter LLP advised Social Finance on the deal. Social Finance, Inc. (SoFi) announced its business combination with SPAC Social Capital Hedosophia Holdings Corp. V (SCH) (NYSE:...
Akili Interactive’s $160 Million Equity and Debt Financing
Goodwin Procter LLP advised Akili Interactive on the deal. Akili Interactive announced its $160 million in combined equity and debt financing. Akili is the maker of EndeavorRx™,...
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
COMPASS Pathways’ $144 Million Shares Offering
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
COMPASS Pathways’ $144 Million Shares Offering
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
Valneva SE’s $107.6 Million Global Offering
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Hogan Lovells and Cooley advised Valneva. Gide advised Goldman Sachs, Jefferies,...
Neuroelectrics’ $17.5 Million Series A Financing
Goodwin Procter LLP advised Neuroelectrics on the deal. Neuroelectrics announced its $17.5 million Series A financing led by Morningside Ventures. Neuroelectrics is developing a therapeutic platform that...
CRISPR Therapeutics’ Collaboration Agreement with Vertex Pharmaceuticals
Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...
CRISPR Therapeutics’ Collaboration Agreement with Vertex Pharmaceuticals
Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...
Cerevel Therapeutics’ $125 Million Non-dilutive Financing Transaction for Tavapadon
Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel...